Get the Stockscreener App
1.29
7.19%
-0.10
After Hours:
1.30
0.01
+0.78%
Tc Biopharm Holdings Plc Adr stock is traded at $1.29, with a volume of 436.10K.
It is down -7.19% in the last 24 hours and down -83.00% over the past month.
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.
See More
Previous Close:
$1.39
Open:
$1.4
24h Volume:
436.10K
Relative Volume:
0.67
Market Cap:
$823.71K
Revenue:
$4.60M
Net Income/Loss:
$-7.33M
P/E Ratio:
0.0277
EPS:
46.49
Net Cash Flow:
$-13.42M
1W Performance:
-20.37%
1M Performance:
-83.00%
6M Performance:
-91.16%
1Y Performance:
-98.63%
1-Day Range:
$1.24
$1.44
1-Week Range:
$1.1226
$1.6337
52-Week Range:
$1.1226
$138.00
Tc Biopharm Holdings Plc Adr Stock (TCBP) Company Profile
Name
Tc Biopharm Holdings Plc Adr
Sector
Industry
Phone
01414337557
Address
MAXIM 1, HOLYTOWN
Tc Biopharm Holdings Plc Adr Stock (TCBP) Latest News
TC BioPharm advances cancer therapy trials, raises $8M By Investing.com - Investing.com South Africa
TC BioPharm advances cancer therapy trials, raises $8M - Investing.com India
TC Biopharm refutes social media claim, remains compliant with Nasdaq rules - TipRanks
TC BioPharm denies Nasdaq delisting rumors - Investing.com
TC Biopharm enters research pact with Dr. Carlos Maluquer de Motes - TipRanks
TC Biopharm (Holdings) PLC – ADR trading halted, volatility trading pause - TipRanks
TCBP Stock Update: TC BioPharm (Holdings) plc ADR’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
TC Biopharm announces artificial intelligene initiative with Carnegie Mellon - TipRanks
TC Biopharm announces first patient completes full dose regimen in ACHIEVE trial - TipRanks
TC BioPharm to start preclinical studies on monkeypox therapy - Investing.com India
TC Biopharm intends to launch preclinical study for treatment of Mpox - TipRanks
TC BioPharm to begin monkeypox treatment studies - Investing.com
TCBP’s Market Moves: -77.03% YTD Growth, -42.22% 6-Month loss, 68.52% in 30 Days - The InvestChronicle
TC BioPharm (Holdings) plc ADR (TCBP)’s stock rises to 7.28 per share - US Post News
TC Biopharm doses five new patients in the ACHIEVE Phase 2b trial in UK - TipRanks
TC Biopharm Unveils New Pre-Funded Warrant - TipRanks
Was there any good news for TC BioPharm (Holdings) plc ADR (TCBP) stock in the last session? - US Post News
Balance Sheet Insights: TC BioPharm (Holdings) plc ADR (TCBP)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
TC BioPharm secures European patent for cell therapy - Investing.com India
TC BioPharm Regains Nasdaq Compliance - TipRanks
TC BioPharm meets Nasdaq equity requirement - Investing.com
TC Biopharm Unveils Pre-Funded Share Warrants - TipRanks
TC BioPharm secures $2 million in direct offering - Investing.com
TC Biopharm Announces Warrant Adjustment - TipRanks
TC Biopharm At Risk of Nasdaq Delisting - TipRanks
Upcoming Stock Splits This Week (August 5 to August 9) – Stay Invested - Yahoo Finance
Apple Hospitality REIT Inc (APLE) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
TC BioPharm adjusts ADS to ordinary share ratio - Investing.com
TC BioPharm Shareholders Approve Key Resolutions - TipRanks
Is TC BioPharm (Holdings) plc ADR (TCBP) worth investing in despite its overvalued state? – US Post News - US Post News
TC BioPharm Reschedules 2024 AGM for July - TipRanks
TC Biopharm Board Members Resign Suddenly - TipRanks
A year in review: TC BioPharm (Holdings) plc ADR (TCBP)'s performance in the last year – US Post News - US Post News
TC BioPharm Announces Dr. Mike Leek as Chief Technology Officer - The Globe and Mail
TC BioPharm Announces Pricing of $5.5 Million Public Offering - The Globe and Mail
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday - The Globe and Mail
TC Biopharm Announces Corporate Restructuring, Reduction in Overhead - The Globe and Mail
Market Highlights: TC BioPharm (Holdings) plc ADR (TCBP) Ends on a Low Note at 1.13 – DWinneX - The Dwinnex
TC BioPharm (Holdings) plc ADR (TCBP) Stock: Navigating Drops and Gains - The InvestChronicle
European Equities Traded in the US as American Depositary Receipts Start Week Off Lower Monday - MSN
Trading Penny Stocks After Hours, Top Tips - PennyStocks
TC BioPharm secures $3.1 million from warrant exercise - Investing.com India
TC BioPharm secures $3.1 million from warrant exercise By Investing.com - Investing.com
Amkor Technology stock rated overweight by JPMorgan, sees strong packaging demand By Investing.com - Investing.com
TC BioPharm eyes expansion with CAR-NK technology LOI - Investing.com
TC BioPharm aims to slash cancer treatment costs By Investing.com - Investing.com
Healthcare Stocks Making Moves Thursday: TCBP, DRRX, CLSD, XRTX, SPRB, IMRX, FWBI, RNXT - InvestorsObserver
symbol__ Stock Quote Price and Forecast - CNN
Healthcare Stocks Making Moves Monday: TCBP, BIAF, LXRX, GRPH, LTRN, OCEA, VTYX, SKYE - InvestorsObserver
TC BioPharm gains MHRA nod for trial amendment By Investing.com - Investing.com
TC Biopharm Plans Share Issuance, Calls Shareholder MeetingTipRanks.com - TipRanks
Tc Biopharm Holdings Plc Adr Stock (TCBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):